Skip to main content
SpringerLink
Log in

Therapie mit neuem Antikörper-Wirkstoff-Konjugat

Signifikanter Überlebensvorteil durch Sacituzumab-Govitecan beim TNBC

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Robert Koch-Institut. 2019;12:16-7; https://doi.org/10.25646/5977 abgerufen am 18. August 2021

  2. Robert Koch-Institut. 2019;12:78-81; https://doi.org/10.25646/5977 abgerufen am 18. August 2021

  3. Gluz O et al. Ann Oncol. 2009;20(12):1913-27

  4. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom abgerufen am 18. August 2021

  5. Park IH et al. Cancer Res Treat. 2019;51(1):43-52

  6. Pivot X et al. Ann Oncol. 2016;27(8):1525-31

  7. Bardia A et al. N Engl J Med. 2019;380(8):741-51

  8. Danielli R et al. 2015;64(1):113-21

  9. Bardia A et al. N Engl J Med. 2021;384(16):1529-41

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie, Christian-Albrechts-Universität zu Kiel, Kiel, Deutschland

    Sebastian Weiße &  Svenja Quaester

  2. Klinik f. Strahlentherapie, Campus Kiel, Arnold-Heller-Str. 3, 24105, Kiel, Deutschland

    Jürgen Dunst

Authors
  1. Sebastian Weiße
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Svenja Quaester
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Dunst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Dunst.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weiße, S., Quaester, S. & Dunst, J. Signifikanter Überlebensvorteil durch Sacituzumab-Govitecan beim TNBC. InFo Hämatol Onkol 24, 29–32 (2021). https://doi.org/10.1007/s15004-021-8782-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8782-8

Search

Navigation